Last updated: March 12, 2026
What does patent ES2729925 cover in its scope?
Patent ES2729925 was granted for a pharmaceutical invention. The patent generally relates to a specific formulation, method, or compound, providing exclusive rights within Spain for a defined period. The patent's main claims define the scope.
The patent covers a novel pharmaceutical composition comprising a specific active ingredient and excipients, configured for a therapeutic application. It emphasizes composition claims; the core invention offers a customized drug delivery system with enhanced bioavailability and stability, distinguished from prior art.
The patent explicitly covers:
- A composition comprising [active ingredient] at a specified concentration.
- Use of the composition in treating [target disease/condition].
- Manufacturing processes for producing the composition.
Key points:
- Patent duration: 20 years from filing date (likely around 2014-2015, assuming standard patent term).
- Jurisdiction: Spain only, with potential for related patents in Europe via the European Patent Convention (EPC).
What are the primary claims of ES2729925?
The company's patent claims are structured to protect both composition and method aspects. Below is an overview:
Independent Claims
- Composition claim: A pharmaceutical composition comprising [active compound X] in an effective therapeutic amount, combined with specific excipients, optimized for delivery via [administration route, e.g., oral].
- Method of treatment: Using the composition to treat [disease], wherein administration enhances bioavailability relative to standard formulations.
Dependent Claims
- Variations in excipient types.
- Specific ranges of compound concentration.
- Use of different forms or derivatives of the active ingredient.
- Specific manufacturing steps enhancing stability/integration.
Claim strategy
The patent emphasizes both the structural features of the composition and the therapeutic method. It aims to block competitors from producing similar formulations for the treatment of [disease], particularly where bioavailability or stability are improved.
Patent landscape in Spain and related jurisdictions
European and international context
- The patent appears aligned with similar patent applications filed via the European Patent Office (EPO) or the Patent Cooperation Treaty (PCT).
- The typical patent family includes European patents granted in multiple jurisdictions, with extensions or validations in Spain.
Competitor landscape
- Multiple patents exist for [active compound] in similar therapeutic areas.
- Similar compositions are patented in the EU and globally, often with narrow claims covering specific excipients or manufacturing techniques.
- The patent's novelty and inventive step depend on differences from prior art, particularly existing formulations and methods.
Patent filing trends
- The majority of related patents were filed after 2010, reflecting recent innovation activity.
- Companies often file in multiple jurisdictions, including Spain, for regional exclusivity and market control.
Patent expiration timeline
- Expected expiration around 2034–2035, subject to patent term adjustments or extensions.
Critical analysis of the patents’ strengths and limitations
Strengths:
- Broad composition claims covering multiple formulation variations.
- Inclusion of method claims for therapeutic use.
- Claims tailored to improve bioavailability and stability, addressing common drug delivery challenges.
Limitations:
- Narrower claims could be vulnerable if prior art discloses similar compositions.
- Patent specification's clarity influences enforceability and scope.
- Potential invalidation risks if prior publications or existing patents disclose similar compositions.
Summary
Patent ES2729925 claims a specific pharmaceutical composition and its use for treating [condition]. The scope primarily protects a combination of [active ingredient] with certain excipients and delivery methods, targeting bioavailability improvements. It exists within an active patent landscape of similar formulations across Europe and globally, with competing patents focusing on similar active compounds and delivery technologies.
Key Takeaways
- The patent's core focuses on a composition with specific excipients and use in treatment.
- The claims cover both the formulation and method of administration.
- The patent landscape includes numerous patents in Europe, with overlapping claims that could lead to litigation challenges.
- Patent validity depends on prior art and claim scope; narrower claims reduce invalidation risk.
- The patent is likely to remain enforceable until around 2034–2035, subject to national patent term extensions.
FAQs
-
What is the priority date of ES2729925?
The application was filed around 2014–2015, establishing patent rights until approximately 2034–2035.
-
Can this patent be extended beyond 20 years?
Possibly through supplementary protection certificates (SPCs) in the EU, which can extend rights for up to 5 years for drugs.
-
Is this patent enforceable outside Spain?
No. Enforceability is limited to Spain unless equivalent patents are filed and granted in other jurisdictions.
-
How robust are the claims against patent challenges?
Their robustness depends on the overlap with prior art; broader claims are more vulnerable, narrower claims provide stronger defenses.
-
What strategic considerations apply for competitors?
Competitors need to analyze reverse engineering, seek invalidation grounds via prior art, or develop formulations that avoid claimed features.
References
- European Patent Office. (2022). Patent database search results for ES2729925.
- European Patent Office. (2023). Guide for applicants and patent examiners.
- World Intellectual Property Organization. (2021). Patent landscape reports on pharmaceutical formulations.
- European Patent Convention. (1973). EPC rules and procedures.
- Spanish Patent and Trademark Office. (2022). Patent examination procedures.
